Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sangamo Therapeutics Inc. buy skatcup

Start price
€15.97
03.04.18 / 50%
Target price
€26.16
22.10.18
Performance (%)
-21.64%
End price
€12.51
22.10.18
Summary
This prediction ended on 22.10.18 with a price of €12.51. The price of Sangamo Therapeutics Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -21.64%. skatcup has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Sangamo Therapeutics Inc. 5.702% 5.702% -57.625% -94.059%
iShares Core DAX® -0.922% -1.078% 12.165% 16.796%
iShares Nasdaq 100 0.371% -0.556% 38.622% 49.370%
iShares Nikkei 225® 2.224% -2.825% 19.015% 4.643%
iShares S&P 500 -0.026% -0.788% 28.485% 42.479%

According to skatcup what are the pros and cons of Sangamo Therapeutics Inc. for the foreseeable future?

Pros
Fair valuation
Strong uniques
Leading role in innovation
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High Investments for future growth
Good culture
Top 10 in its market
Very small cyclical dependencies
Known brand
Very Future proof/growth oriented business model
Cons
Bad rating
Very low/no dividend yield expected
Risky balance sheet
Higher risks for its business

Comments by skatcup for this prediction

In the thread Sangamo Bioscienes diskutieren
Prediction Buy
Perf. (%) -21.64%
Target price 26.158
Change
Ends at 22.10.18

skatcup stimmt dem Sentiment von 'Buy' zu

skatcup stimmt am 03.04.2018 dem Buy-Gesamtsentiment mit dem Kursziel 23.2$ zu.

Prediction Buy
Perf. (%) -21.64%
Target price 26.158
Change
Ends at 22.10.18

(Vom Mitglied beendet)

Stopped prediction by skatcup for Sangamo Therapeutics Inc.

buy
Sangamo Therapeutics Inc.

Start price
Target price
Perf. (%)
€8.74
31.05.21
€15.00
31.05.22
-60.61%
01.06.22

Fair valuation
Strong uniques
Leading role in innovation
Bad rating